Serveur d'exploration sur l'agrobacterium et la transgénèse

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

[Tobacco--a highly efficient producer of vaccines].

Identifieur interne : 000588 ( Main/Exploration ); précédent : 000587; suivant : 000589

[Tobacco--a highly efficient producer of vaccines].

Auteurs : Jaromir Budzianowski [Pologne]

Source :

RBID : pubmed:21360963

Descripteurs français

English descriptors

Abstract

Along with the depreciation of tobacco as a source of nicotine-containing commercial products, the increase of its appreciation as a potential producer of recombinant therapeutical proteins can be observed. Two species of tobacco--Nicotiana tabacum L. and N. benthamiana are easily grown by well established methods of field or green-house cultivation or cell culture, yield high biomass and soluble protein content, can be easily transformed by several methods and are not food for humans or feed for animals. Expression of foreign proteins, including vaccines, can be achieved in those plants either through stable transformation of nuclear or plastid (chloroplast) genomes or by transient transformation using infection with plant virus or bacteria--Agrobacterium tumefaciens (agroinfiltration). The most advanced mode of agrofiltration termed magnifection, which combines benefits of virus and Agrobacterium and depends on using Agrobacterium with viral pro-vectors, enables high-yield and rapid expression of therapeutical proteins, even in a few days, and can be employed on an industrial scale. Expression of many antigenic proteins, which may serve as antiviral, antibacterial, antiprotozoan and anticancer vaccines, and additionally a few autoantigens designed for the treatment of autoimunogenic diseases, like diabetes, have been achieved in tobacco. To date, a vaccine against Newcastle virus disease in poultry produced by tobacco cell culture has been approved for commercial application and several other vaccines are in advanced stage of development. The possibility of a high-level production of vaccines in tobacco against pandemic influenza or anthrax and plague due to a bioterroristic attack, as well as of individualised anticancer vaccines against non-Hodgkin's lymphoma (NHL) in a much shorter period of time than by traditional methods became realistic and hence caused increased interest in tobacco as a high-efficient producer of vaccines not only of specialistic biotechnology firms but also a big pharmaceutical corporation and a department of defence.

PubMed: 21360963


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">[Tobacco--a highly efficient producer of vaccines].</title>
<author>
<name sortKey="Budzianowski, Jaromir" sort="Budzianowski, Jaromir" uniqKey="Budzianowski J" first="Jaromir" last="Budzianowski">Jaromir Budzianowski</name>
<affiliation wicri:level="1">
<nlm:affiliation>Katedra i Zakład Botaniki Farmaceutycznej i Biotechnologii Roślin, Uniwersytet Medyczny im. Karola Marcinkowskiego, Poznań. jbudzian@ump.edu.pl</nlm:affiliation>
<country wicri:rule="url">Pologne</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:21360963</idno>
<idno type="pmid">21360963</idno>
<idno type="wicri:Area/Main/Corpus">000609</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000609</idno>
<idno type="wicri:Area/Main/Curation">000609</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000609</idno>
<idno type="wicri:Area/Main/Exploration">000609</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">[Tobacco--a highly efficient producer of vaccines].</title>
<author>
<name sortKey="Budzianowski, Jaromir" sort="Budzianowski, Jaromir" uniqKey="Budzianowski J" first="Jaromir" last="Budzianowski">Jaromir Budzianowski</name>
<affiliation wicri:level="1">
<nlm:affiliation>Katedra i Zakład Botaniki Farmaceutycznej i Biotechnologii Roślin, Uniwersytet Medyczny im. Karola Marcinkowskiego, Poznań. jbudzian@ump.edu.pl</nlm:affiliation>
<country wicri:rule="url">Pologne</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Przeglad lekarski</title>
<idno type="ISSN">0033-2240</idno>
<imprint>
<date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Biomass (MeSH)</term>
<term>Genetic Vectors (MeSH)</term>
<term>Plants, Genetically Modified (MeSH)</term>
<term>Recombinant Proteins (biosynthesis)</term>
<term>Species Specificity (MeSH)</term>
<term>Tobacco (classification)</term>
<term>Tobacco (virology)</term>
<term>Transfection (MeSH)</term>
<term>Viral Vaccines (biosynthesis)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Biomasse (MeSH)</term>
<term>Protéines recombinantes (biosynthèse)</term>
<term>Spécificité d'espèce (MeSH)</term>
<term>Tabac (classification)</term>
<term>Tabac (virologie)</term>
<term>Transfection (MeSH)</term>
<term>Vaccins antiviraux (biosynthèse)</term>
<term>Vecteurs génétiques (MeSH)</term>
<term>Végétaux génétiquement modifiés (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en">
<term>Recombinant Proteins</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr">
<term>Protéines recombinantes</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en">
<term>Tobacco</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr">
<term>Tabac</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en">
<term>Tobacco</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Biomass</term>
<term>Genetic Vectors</term>
<term>Plants, Genetically Modified</term>
<term>Species Specificity</term>
<term>Transfection</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="fr">
<term>Biomasse</term>
<term>Spécificité d'espèce</term>
<term>Tabac</term>
<term>Transfection</term>
<term>Vecteurs génétiques</term>
<term>Végétaux génétiquement modifiés</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Along with the depreciation of tobacco as a source of nicotine-containing commercial products, the increase of its appreciation as a potential producer of recombinant therapeutical proteins can be observed. Two species of tobacco--Nicotiana tabacum L. and N. benthamiana are easily grown by well established methods of field or green-house cultivation or cell culture, yield high biomass and soluble protein content, can be easily transformed by several methods and are not food for humans or feed for animals. Expression of foreign proteins, including vaccines, can be achieved in those plants either through stable transformation of nuclear or plastid (chloroplast) genomes or by transient transformation using infection with plant virus or bacteria--Agrobacterium tumefaciens (agroinfiltration). The most advanced mode of agrofiltration termed magnifection, which combines benefits of virus and Agrobacterium and depends on using Agrobacterium with viral pro-vectors, enables high-yield and rapid expression of therapeutical proteins, even in a few days, and can be employed on an industrial scale. Expression of many antigenic proteins, which may serve as antiviral, antibacterial, antiprotozoan and anticancer vaccines, and additionally a few autoantigens designed for the treatment of autoimunogenic diseases, like diabetes, have been achieved in tobacco. To date, a vaccine against Newcastle virus disease in poultry produced by tobacco cell culture has been approved for commercial application and several other vaccines are in advanced stage of development. The possibility of a high-level production of vaccines in tobacco against pandemic influenza or anthrax and plague due to a bioterroristic attack, as well as of individualised anticancer vaccines against non-Hodgkin's lymphoma (NHL) in a much shorter period of time than by traditional methods became realistic and hence caused increased interest in tobacco as a high-efficient producer of vaccines not only of specialistic biotechnology firms but also a big pharmaceutical corporation and a department of defence.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">21360963</PMID>
<DateCompleted>
<Year>2011</Year>
<Month>08</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised>
<Year>2011</Year>
<Month>03</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0033-2240</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>67</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2010</Year>
</PubDate>
</JournalIssue>
<Title>Przeglad lekarski</Title>
<ISOAbbreviation>Przegl Lek</ISOAbbreviation>
</Journal>
<ArticleTitle>[Tobacco--a highly efficient producer of vaccines].</ArticleTitle>
<Pagination>
<MedlinePgn>1071-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Along with the depreciation of tobacco as a source of nicotine-containing commercial products, the increase of its appreciation as a potential producer of recombinant therapeutical proteins can be observed. Two species of tobacco--Nicotiana tabacum L. and N. benthamiana are easily grown by well established methods of field or green-house cultivation or cell culture, yield high biomass and soluble protein content, can be easily transformed by several methods and are not food for humans or feed for animals. Expression of foreign proteins, including vaccines, can be achieved in those plants either through stable transformation of nuclear or plastid (chloroplast) genomes or by transient transformation using infection with plant virus or bacteria--Agrobacterium tumefaciens (agroinfiltration). The most advanced mode of agrofiltration termed magnifection, which combines benefits of virus and Agrobacterium and depends on using Agrobacterium with viral pro-vectors, enables high-yield and rapid expression of therapeutical proteins, even in a few days, and can be employed on an industrial scale. Expression of many antigenic proteins, which may serve as antiviral, antibacterial, antiprotozoan and anticancer vaccines, and additionally a few autoantigens designed for the treatment of autoimunogenic diseases, like diabetes, have been achieved in tobacco. To date, a vaccine against Newcastle virus disease in poultry produced by tobacco cell culture has been approved for commercial application and several other vaccines are in advanced stage of development. The possibility of a high-level production of vaccines in tobacco against pandemic influenza or anthrax and plague due to a bioterroristic attack, as well as of individualised anticancer vaccines against non-Hodgkin's lymphoma (NHL) in a much shorter period of time than by traditional methods became realistic and hence caused increased interest in tobacco as a high-efficient producer of vaccines not only of specialistic biotechnology firms but also a big pharmaceutical corporation and a department of defence.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Budzianowski</LastName>
<ForeName>Jaromir</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Katedra i Zakład Botaniki Farmaceutycznej i Biotechnologii Roślin, Uniwersytet Medyczny im. Karola Marcinkowskiego, Poznań. jbudzian@ump.edu.pl</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>pol</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>Tytoń--wysokowydajny producent szczepionek.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>Poland</Country>
<MedlineTA>Przegl Lek</MedlineTA>
<NlmUniqueID>19840720R</NlmUniqueID>
<ISSNLinking>0033-2240</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D018533" MajorTopicYN="N">Biomass</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D030821" MajorTopicYN="N">Plants, Genetically Modified</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014026" MajorTopicYN="N">Tobacco</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2011</Year>
<Month>3</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2010</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2011</Year>
<Month>8</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">21360963</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Pologne</li>
</country>
</list>
<tree>
<country name="Pologne">
<noRegion>
<name sortKey="Budzianowski, Jaromir" sort="Budzianowski, Jaromir" uniqKey="Budzianowski J" first="Jaromir" last="Budzianowski">Jaromir Budzianowski</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/AgrobacTransV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000588 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000588 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    AgrobacTransV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:21360963
   |texte=   [Tobacco--a highly efficient producer of vaccines].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:21360963" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AgrobacTransV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Fri Nov 20 15:45:55 2020. Site generation: Wed Mar 6 15:24:41 2024